Inventor
YAMANAKA MARK
US15 patents
⚠️ This page may combine multiple inventors who share the name “YAMANAKA MARK”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
SQUIBB & SONS LLC
11 patentsUS10344089B2Jul 9, 2019
Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof
SQUIBB & SONS LLC25 citations97
US11001630B2May 11, 2021
Human antibodies that bind lymphocyte activation Gene-3 (LAG-3), and uses thereof
SQUIBB & SONS LLC10 citations94
US10988535B2Apr 27, 2021
Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof
SQUIBB & SONS LLC10 citations94
US10988536B2Apr 27, 2021
Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof
SQUIBB & SONS LLC10 citations94
US11530267B2Dec 20, 2022
Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof
SQUIBB & SONS LLC2 citations84
US11512130B2Nov 29, 2022
Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof
SQUIBB & SONS LLC2 citations84
US11236163B2Feb 1, 2022
Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof
SQUIBB & SONS LLC4 citations84
US11236165B2Feb 1, 2022
Human antibodies that bind Lymphocyte Activation Gene-3 (LAG-3), and uses thereof
SQUIBB & SONS LLC4 citations84
US11236164B2Feb 1, 2022
Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof
SQUIBB & SONS LLC4 citations84
US9499632B2Nov 22, 2016
Human antibodies that bind CD22 and uses thereof
SQUIBB & SONS LLC8 citations82
US9217033B2Dec 22, 2015
Monoclonal antibodies against Glypican-3
SQUIBB & SONS LLC1 citations50